Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

138 recruiting

Showing 120 of 306 trials

Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled500 locationsNCT05987241
Recruiting
Phase 2

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia
National Cancer Institute (NCI)147 enrolled227 locationsNCT06317649
Recruiting
Phase 2

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled345 locationsNCT03191149
Recruiting
Phase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled348 locationsNCT05564390
Recruiting
Phase 2

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled225 locationsNCT05554406
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting
Not Applicable

Zenith® Fenestrated+ Clinical Study

Juxtarenal Aortic AneurysmAortic Aneurysm, AbdominalPararenal Aneurysm+1 more
Cook Research Incorporated105 enrolled33 locationsNCT04875429
Recruiting

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmImmune System Disorder
Alliance for Clinical Trials in Oncology2,240 enrolled625 locationsNCT04242095
Recruiting
Not Applicable

ELEVATE High-Risk PCI Pivotal Study

High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled33 locationsNCT07001332
Recruiting
Not Applicable

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

Emphysema or COPDEmphysema, Pulmonary
Pulmonx Corporation200 enrolled36 locationsNCT06035120
Recruiting
Not Applicable

Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Mitral Valve Regurgitation
Medtronic Cardiovascular1,056 enrolled85 locationsNCT03242642
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled22 locationsNCT07326566
Recruiting
Phase 2

ALPINE: Maintenance Letrozole/Abemaciclib

Endometrial CancerTP53Recurrent Endometrial Cancer
Dana-Farber Cancer Institute32 enrolled6 locationsNCT06366347
Recruiting
Not Applicable

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

Aortic Valve InsufficiencyAortic Insufficiencyaortic regurgitation
JenaValve Technology, Inc.1,016 enrolled29 locationsNCT06608823
Recruiting
Phase 2

ELISA in Relapsed/Refractory MM

Relapsed/Refractory Multiple MyelomaRelapsed Refractory Multiple Myeloma (RRMM)
Massachusetts General Hospital30 enrolled3 locationsNCT06832865
Recruiting
Not Applicable

Diagnosing Epilepsy To EffeCT Change

EpilepsyEpilepsy (Treatment Refractory)
Epiminder America, Inc.210 enrolled19 locationsNCT07110337
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled168 locationsNCT06091865
Recruiting
Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis
Gilead Sciences402 enrolled205 locationsNCT06051617
Recruiting

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Peripheral Vascular Diseases
Boston Scientific Corporation5,000 enrolled80 locationsNCT04674969